Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.
about
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteinsVaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stabilityAdvances in aluminum hydroxide-based adjuvant research and its mechanismKinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaquesStability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solutionImmunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response.Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.Thermal aggregation of recombinant protective antigen: aggregate morphology and growth rateComparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
P2860
Q24562788-2D049023-DB12-49B9-B4BD-95D8F5C6B2B5Q24634332-23F84E13-D5AD-42EF-A85C-81B13A044A80Q27007659-DA830391-E1A7-4121-BD01-5B457AB8782FQ28389893-1CD7CFC2-1B62-47B3-82A6-7BAB42EF0B38Q30371202-2975687D-F04E-4C12-9EEC-D4F32829AA3AQ30859738-0982AC12-60B2-47AB-909A-9731A7227071Q33302902-6135A1A7-618D-4412-A555-89B183FAFD6AQ33368131-1AE3B746-3EEB-45D4-A8D2-1B688B857BF1Q33883273-D7DBC226-BCE6-4C0F-9D3C-8F6205B4221FQ34194649-E5CF9AAC-09F6-4BE3-8BC6-D84775859C75Q34615921-CDF942FF-9539-4FEA-ADD4-4E02B6C9CC09Q35887653-5DA35E8B-5802-4426-BCD7-EB74E95408F3Q35935173-C9E21D49-03A9-4894-8235-F6DF82C957C2Q36968256-2ADE52C9-FBDA-434A-8E8F-DFC2A6E72EADQ57478910-16BFBB73-6A89-435E-BF4D-FEA07206480A
P2860
Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evaluation of the compatibilit ...... aluminum-containing adjuvants.
@ast
Evaluation of the compatibilit ...... aluminum-containing adjuvants.
@en
type
label
Evaluation of the compatibilit ...... aluminum-containing adjuvants.
@ast
Evaluation of the compatibilit ...... aluminum-containing adjuvants.
@en
prefLabel
Evaluation of the compatibilit ...... aluminum-containing adjuvants.
@ast
Evaluation of the compatibilit ...... aluminum-containing adjuvants.
@en
P2093
P1433
P1476
Evaluation of the compatibilit ...... aluminum-containing adjuvants.
@en
P2093
Gautam Mitra
Scott Jendrek
Stanley Hem
Stephen F Little
Steven Giardina
P304
P356
10.1016/S0264-410X(03)00109-9
P407
P577
2003-06-01T00:00:00Z